Abstract
Background. Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy. Two BTK inhibitors, ibrutinib and zanubrutinib, are FDA approved for relapsed/refractory MZL patients. PI3K inhibitors have also shown clinical activity although their use has been recently reduced due to toxicities. We have previously reported a model of resistance to BTK/PI3K inhibitors developed by prolonged exposure to the PI3K-delta inhibitor idelalisib (Arribas, ASH2019). Here, we present the data from a large pharmacological screen with over 1,500 compounds in this MZL model.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
